Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.40 |
| ▸ | NOS1 | P29475 | 4/20 | 0.38 |
| ▸ | NOS2 | P35228 | 4/20 | 0.38 |
| ▸ | NOS3 | P29474 | 3/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10137676 | 0.88 | CYP3A4 (0.55) | CYP3A4GPR119 | |
| SCHEMBL304381 | 0.86 | GPR119 (0.47) | CYP3A4GPR119NOS1NOS2NOS3 | |
| SCHEMBL304382 | 0.86 | GPR119 (0.47) | CYP3A4GPR119NOS1NOS2NOS3 | |
| SCHEMBL9972354 | 0.75 | CYP3A4 (0.53) | CYP3A4GPR119 | |
| SCHEMBL27755048 | 0.74 | GPR119 (0.58) | CYP3A4GPR119 | |
| SCHEMBL2021773 | 0.73 | GPR119 (0.67) | CYP3A4GPR119 | |
| SCHEMBL304560 | 0.73 | NOS2 (0.44) | NOS1NOS2NOS3BTK | |
| SCHEMBL304206 | 0.72 | CYP3A4 (0.46) | CYP3A4GPR119NPY2R | |
| SCHEMBL3748505 | 0.71 | IKBKB (0.60) | — | |
| SCHEMBL3285206 | 0.70 | GPR119 (0.65) | GPR119NPY2RPRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476283-B2 | [6,5]—bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2152707-B1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20120077826-A1 | [6,5] - BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-29 | — | — | US | disclosed |
| US-8093257-B2 | [6,5]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2152707-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090018055-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| WO-2008137436-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018055-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR139, GPR4 | CYP3A4 1283/4885GPR119 1/4885NOS1 2062/4885 |
| US-20120077826-A1 | [6,5] - BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR139, GPR4 | CYP3A4 1283/4885GPR119 1/4885NOS1 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.